Commercially Available Prostaglandin Analogs for the Reduction of Intraocular Pressure: Similarities and Differences

  • Bean G
  • Camras C
  • 28


    Mendeley users who have this article in their library.
  • 54


    Citations of this article.


Over the last 12 years, the pharmacological management of glaucoma and ocular hypertension has significantly changed with the introduction of the prostaglandin analogs, specifically, latanoprost, bimatoprost, and travoprost. Their ability to effectively reduce intraocular pressure with once-per-day dosing, their comparable ocular tolerability with timolol, and their general lack of systemic side effects have made them the mainstay of pharmacological therapy for glaucoma and ocular hypertension in most parts of the world. A review of their pharmacology reveals that they are all prodrugs that are converted to their respective free acids within the eye to activate the prostanoid FP receptor and to reduce intraocular pressure by enhancing the uveoscleral and the trabecular meshwork outflow pathways. A review of numerous prospective, randomized comparative studies indicates that no clinically significant differences exist among these agents regarding their ability to lower intraocular pressure. © 2008 Elsevier Inc. All rights reserved.

Author-supplied keywords

  • bimatoprost
  • glaucoma
  • intraocular pressure
  • latanoprost
  • ocular hypertension
  • prodrug
  • prostaglandin
  • prostaglandin ethanolamide
  • travoprost

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


  • Gerald W. Bean

  • Carl B. Camras

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free